HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a $32 price target on the stock.
January 22, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reaffirms a Buy rating on Verona Pharma with a $32 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $32 price target by a reputable analyst could lead to increased investor confidence in VRNA, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100